Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 8Recruiting 7Completed 5Unknown 3Not yet recruiting 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 5Head & Neck 3Tumor-Agnostic 2Gastrointestinal 2Other solid neoplasm 1CNS 1

Conditions

Thyroid Neoplasms 3

Interventions

Cisplatin 108Radiotherapy 45Docetaxel 44Radiotherapy, Intensity-Modulated 36Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13Blood Specimen Collection 13sintilimab 12nimotuzumab 12Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × trametinib × Head & Neck × Clear all
NCT05182931 2023-10-31

I-FIRST

Olivia Newton-John Cancer Research Institute

Phase 2 Unknown
80 enrolled
Head & Neck

Thyroid Neoplasms

NCT04619316 2023-06-22

ERRITI

University Hospital, Essen

Phase 2 Unknown
70 enrolled
Head & Neck

Thyroid Neoplasms

NCT04554680 2021-03-05

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

National University Hospital, Singapore

Phase 2 Unknown
5 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡